Lifecore Biomedical, Inc. De (LFCR) Net Margin (2010 - 2025)

Lifecore Biomedical has reported Net Margin for 16 years, with the latest figure at 24.72% in Q2 2025.

• On a quarterly basis, Net Margin fell 603.0% year-over-year to 24.72% in Q2 2025; TTM through May 2025 was 35.54%, a 4490.0% decrease from a year earlier, with the FY2025 full-year figure at 34.42%, down 4379.0% from the prior year.
• Net Margin was 24.72% for Q2 2025 at Lifecore Biomedical, up from 44.53% in the prior quarter.
• The five-year high for Net Margin was 47.16% in Q4 2023, with the low at 198.32% in Q2 2022.
• Average Net Margin over 5 years is 55.87%, with a median of 44.19% recorded in 2025.
• The sharpest annual moves came in 2022 and 2024: Net Margin slumped 16107 bps in 2022, then surged 18136 bps in 2024.
• Over 5 years, Net Margin stood at 150.27% in 2021, then surged by 61 bps to 58.57% in 2022, then surged by 181 bps to 47.16% in 2023, then plunged by 157 bps to 26.73% in 2024, then advanced by 7 bps to 24.72% in 2025.
• The last three Net Margin figures came in at 24.72% (Q2 2025), 44.53% (Q1 2025), and 26.73% (Q4 2024), per Business Quant data.